SUBCUTANEOUS DRUG ADMINISTRATION DEVICE
A single rotor system simplifies the subcutaneous drug administration device by controlling fluid path opening and injection needle movement, reducing costs and complexity while ensuring precision and safety.
Patent Information
- Application Number
- FR2023013415
- Authority / Receiving Office
- FR · FR
- Patent Type
- Utility models
- Current Assignee / Owner
- Priority Date
- 2022-12-01
- Filing Date
- 2023-12-01
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2033-12-01
AI Technical Summary
Existing subcutaneous drug administration devices are complex in terms of components and movements, leading to high production and purchasing costs, and there is a need to simplify these devices without compromising precision and safety.
A device with a single rotor that rotates in opposite directions to control a fluid path opening system and an injection needle movement mechanism, using a single movement transmission member to simplify operations and reduce component count.
Reduces production and purchase costs while maintaining precision and safety by simplifying the device's components and movements, ensuring synchronization without increasing complexity.
Smart Images

Figure 00000033_0000 
Figure 00000034_0000 
Figure 00000035_0000
Abstract
Description
Title of the invention: DEVICE FOR SUBCUTANEOUS ADMINISTRATION OF A MEDICINE Technical field of the invention
[0001] The present invention relates to a device for subcutaneous administration of a drug.
[0002] In particular, the device of the present invention falls within the category of "infusion pumps" as defined by the FDA (US Food and Drug Administration) and relates, more particularly, to a device of the type that can be worn on oneself, that is to say configured to be applied to the body of a patient in order to allow the subcutaneous administration of a predetermined dose of medication. The application of the device to the patient's body is carried out by a user, for example a doctor or a nurse or the patient. Technical background
[0003] Examples of delivery devices of the type discussed above are described in EP 3439715B1 and WO 2020 / 128821A1.
[0004] In all wearable delivery devices, the drug is initially contained in a cartridge housed within the device and is transferred into the patient's body via a fluid path.
[0005] In the present application, the term "fluidic path" is used to designate any element or set of elements which is configured to be connected, at a first end thereof, to the cartridge housed inside the administration device and comprising, at an end thereof opposite the first end mentioned above, an injection needle intended to be inserted into the patient's body to allow the transfer of the medicament from the cartridge to the patient's body.
[0006] Typically, the cartridge comprises a cylindrical container, made of a plastic or glass material, a plunger slidable within the container to push the drug out of the container and a pierceable septum which ensures the sterility of the container until the administration of the therapy begins.
[0007] Typically, the fluid path includes a piercing needle configured to pierce the pierceable septum of the cartridge and a flexible tube that places the piercing needle in fluid communication with the injection needle.
[0008] In such devices, the cartridge container is kept closed by the pierceable septum until administration of the drug is required. When such administration is required, the piercing needle pierces the pierceable septum and opens the fluid path, allowing the drug to reach the patient by passing first through the piercing needle, then through the flexible tube and finally through the injection needle, due to the thrust exerted by the plunger on the medicine inside the container.
[0009] Obviously, the administration of the drug to the patient takes place after the insertion of the injection needle into the patient's body.
[0010] Such insertion occurs following activation of an injection needle moving mechanism configured to move the injection needle between a rest position in which the injection needle is fully disposed within the device and an injection position in which the injection needle protrudes from the device and penetrates the patient's skin.
[0011] The injection needle moving mechanism may also be configured to extract the injection needle from the patient's skin upon completion of therapy delivery back into the device.
[0012] The Applicant has observed that the various components of the devices described above must act in synchronization to ensure that the administration of the drug takes place accurately and under maximum safety conditions for the patient. However, there is a need to ensure this synchronization without making the device too complex both in terms of the number of components and in terms of their movement.
[0013] WO 2020 / 128821A1 describes a device comprising a single rotor which rotates in the two opposite rotational directions to drive the delivery of the drug and the movement of the injection needle, respectively.
[0014] The Applicant felt the need to further simplify the production and assembly of the above-mentioned devices in order to reduce the production cost and, consequently, the purchase cost.
[0015] The Applicant has understood that this need can be met not only by providing a single rotor which, by rotating in the two opposite directions, causes the drug to be delivered and the injection needle to be moved, but also by providing a single transmission member which, by rotating in the same direction of rotation, causes the fluid path to be opened and the injection needle to be extracted from the device for the administration of the therapy. Summary of the Invention
[0016] The present invention therefore relates, in a first aspect thereof, to a device for subcutaneous administration of a medicament, comprising: - a cartridge comprising a container containing the medicament, a piston slidable in said container and a pierceable septum coupled to one end of said container; - a piercing needle configured to pierce the pierceable septum; - an injection needle configured to inject the medicament into a patient, said injection needle defining, with said piercing needle, a fluid path configured to be traveled by the medicament during subcutaneous administration of the medicament; - a fluid path opening system configured to partially insert the piercing needle into the pierceable septum and thereby place the injection needle in fluid communication with the container through the piercing needle; - an injection needle moving mechanism configured to move the injection needle between a rest position in which the injection needle is fully disposed within the device and an injection position in which the injection needle protrudes at least partially from the device; - a drug delivery mechanism configured to controllably move the plunger in the container toward the pierceable septum; - a rotor configured to control the fluid path opening system, the injection needle moving mechanism and the drug delivery mechanism; - a control unit configured to drive the rotor alternately in a first direction of rotation and in a second direction of rotation opposite to the first direction of rotation; - a first motion transmission member connected to the rotor and configured to drive the fluid path opening system and the injection needle movement mechanism by rotation of the rotor in said first direction of rotation; - a second motion transmission member connected to the rotor and configured to drive the drug delivery mechanism by rotation of the rotor in said second direction of rotation.
[0017] In a second aspect thereof, the present invention relates to a method for carrying out subcutaneous administration of a medicament through a device according to any one of the preceding claims, comprising, in this order: - detection if the device is applied to the patient's skin; - activating the fluid path opening system by the first motion transmission member by rotating the rotor in said first direction of rotation for a first time interval; - driving the drug delivery mechanism by the second motion transmission member by rotating the rotor in said second direction of rotation for a third time interval, causing the piston to move into the container without delivery of the drug through the injection needle; - driving the injection needle moving mechanism by the first motion transmission member by rotating the rotor in said first rotational direction for a second time interval, causing the injection needle to move from the rest position to the injection position; - driving the drug delivery mechanism by the second motion transmission member by rotating the rotor in said second rotational direction for a fourth time interval, causing the piston to move in the container without administering the drug through the injection needle.
[0018] According to the present invention, the desired reduction in the production and purchasing costs of the device is achieved by reducing the number of components required to carry out the various operating phases of the device. In particular, a single rotor is provided which, when rotating in one direction, drives a single motion transmission member, which in turn causes the fluid path to open and the injection needle to be extracted from the device. When, on the other hand, the rotor rotates in the opposite direction, it drives another motion transmission member, which in turn causes the drug to be administered to the patient through the fluid path.
[0019] Preferred features of the invention are described below. Each of these features may be provided individually or in combination with the others.
[0020] Preferably, the first motion transmission member is configured to activate the fluid path opening system when the rotor rotates in the first rotational direction for a first time interval.
[0021] Preferably, the first motion transmission member is configured to activate the injection needle movement mechanism when the rotor rotates in the first rotational direction for a second time interval.
[0022] Preferably, the second time interval is later than the first time interval.
[0023] Therefore, the first motion transmission member first opens the fluid path and only subsequently causes the injection needle to be extracted from the device. The execution of two operating phases is therefore temporarily separated despite the fact that it is driven by the same motion transmission member.
[0024] Preferably, the device comprises a protective element movable between a first operating position in which the protective element projects from the device and a second operating position in which the protective element does not project from the device. This protective element makes it possible to protect the patient against accidental contact with the injection needle. when the device is not applied to the patient's skin, if the injection needle is outside the device.
[0025] Preferably, it is provided that the protective element is in the first operating position before applying the device to the patient's skin and covers the injection needle if, for any reason, it is outside the device. In fact, although it is provided that before applying the device to the patient's skin, the injection needle is inside the device, it cannot be excluded that due to a malfunction or failure of the injection needle moving mechanism, it emerges from the device.
[0026] The device preferably further comprises a stopping mechanism configured to stop the movement of the protective element.
[0027] More preferably, the stop mechanism comprises a stop element and the protective element comprises a locking element configured to cooperate with the stop element and to lock the protective element in the first operating position when the device is removed from the patient's skin. In this way, if the injection needle remains outside the device at the end of the administration of the therapy or if the device is accidentally or intentionally removed from the patient's skin before the end of the administration of the therapy, the protective element immediately comes out of the device and remains locked in the extracted position, also preventing in this case the patient from being able to come into contact with the injection needle.
[0028] Preferably, the first motion transmission member is configured to drive the stop mechanism when the rotor rotates in the first direction of rotation for a given time interval. Locking of the protective element once the device is removed from the patient's skin is therefore performed by the same motion transmission member that is used to open the fluid path and extract the injection needle, benefiting the production and purchase costs of the device.
[0029] Preferably, said given time interval coincides at least in part with the second time interval.
[0030] More preferably, the given time interval mentioned above coincides exactly with the second time interval. The activation of the protective element stopping mechanism therefore takes place simultaneously with the activation of the injection needle moving mechanism, so as to be sure that, in the event that the device is removed from the patient's skin before the end of the administration of the therapy, the protective element, once removed from the device, remains locked in position outside the device.
[0031] Alternative embodiments are, however, contemplated in which the given time interval mentioned above is later than the second time interval.
[0032] Preferably, the first motion transmission member comprises a rack movable along a first direction and a worm screw coupled to the rack.
[0033] Preferably, the worm screw is coupled to an instruction member which controls the injection needle movement mechanism.
[0034] Preferably, the rack comprises a first coupling portion configured to drive a drive member of the fluid path opening system during movement of the rack along said first direction.
[0035] Preferably, the rack comprises a second coupling portion arranged upstream of the first coupling portion along said first direction and coupled to the worm screw.
[0036] The rotation of the worm screw thus causes the injection needle to be extracted from the device and the rack to move along the first direction. This movement causes the fluid path to open.
[0037] Preferably, the stop element is associated with a third coupling part of the rack arranged upstream relative to the first coupling part along said first direction.
[0038] Preferably, said third coupling portion is interposed between said first coupling portion and said second coupling portion. It is therefore ensured that, when the device is removed from the patient's skin and the protective element exits the device, it immediately remains locked in position outside the device.
[0039] Preferably, after driving the drug delivery mechanism by the second motion transmission member by rotating the rotor in said second rotational direction for said fourth time interval, the injection needle moving mechanism is driven by the first motion transmission member by rotating the rotor in said first rotational direction for a fifth time interval, causing the injection needle to move from the injection position to the rest position.
[0040] Preferably, after activating the fluid path opening system by the first motion transmission member by rotating the rotor in said first rotational direction for said first time interval and before removing the device from the patient's skin, the protective element stopping mechanism is driven by the first motion transmission member by rotating the rotor in said first rotational direction for a given time interval.
[0041] Preferably, said given time interval coincides at least in part with said second time interval.
[0042] Preferably, activating the fluid path opening system and driving the protective element stopping mechanism both comprise moving the rack along said first direction.
[0043] Preferably, the device comprises a position sensor configured to detect contact of the device with the patient's skin. By means of the above-mentioned sensor, it is ensured that the device cannot be put into operation before being applied to the patient's body or, in other words, it is ensured that the device can only be put into operation when it is actually in the condition to be able to administer the medicament. This is particularly advantageous because the medicaments used in these devices are typically very expensive and because, to ensure patient safety conditions, the device is considered to have been used immediately after its putting into operation, regardless of whether the medicament has actually been administered to the patient or whether such administration is successful.
[0044] Preferably, the device comprises an administration module and a control module which can be mutually coupled and decoupled.
[0045] Preferably, the administration module is disposable while the control module is reusable.
[0046] Preferably, the rotor comprises a drive rotor and a magnetic rotor.
[0047] Preferably, the administration module comprises the magnetic rotor, the cartridge, the fluid path, the fluid path opening system, the injection needle moving mechanism, the drug delivery mechanism, the first motion transmission member, the second motion transmission member, while the control module comprises the drive rotor, a drive motor for driving the drive rotor and the control unit.
[0048] The protection element, if provided, is associated with the administration module.
[0049] The position sensor, if provided, preferably comprises a magnet housed in the administration module and a Hall effect sensor housed in the control module.
[0050] In preferred embodiments, the magnet is integrally associated with the protective element.
[0051] Preferably, the administration module comprises an ignition magnet.
[0052] Preferably, the control module comprises a switch for supplying power to energy the control unit.
[0053] Preferably, the device is activated by the patient by pressing a specific activation button.
[0054] Preferably, the activation button is arranged on the control unit.
[0055] Preferably, the control module comprises a plurality of electronic components Ironic and a hardware unit that supplies power to said electronic components. Therefore, before being put into operation, the device is in a sleep mode.
[0056] Preferably, the control module comprises an NFC tag on which a plurality of information is stored.
[0057] Preferably, before putting the device into operation, the administration module and the control module are coupled to each other. This coupling causes the control unit to be powered up because the ignition magnet, which is close to the switch that supplies power to the control unit, triggers it.
[0058] Preferably, after power-up, the control unit performs a self-diagnosis.
[0059] Preferably, after power-up, the control unit interrogates the NFC tag by reading the information stored therein. In particular, the control unit performs any or all of the following actions: checking whether the administration module has already been used, checking whether the administration module is configured to administer a correct dosage of the drug, setting the method of administering the drug, setting the rate of administering the drug.
[0060] Preferably, after power-up, the control unit reads the signal from the position sensor to establish whether the device is in contact with the patient's skin.
[0061] Preferably, if the control unit does not detect the signal from the position sensor within a predetermined period of time, the control unit turns off. The device then returns to standby mode. Brief description of the figures
[0062] Other features and advantages of the present invention will become clearer upon reading the following detailed description of preferred embodiments thereof, made with reference to the accompanying drawings and given for informational and non-limiting purposes. In these drawings:
[0063] [Fig.l] - [Fig.l] is a perspective view of a device according to the present invention;
[0064] [Fig.2] - [Fig.2] is an exploded perspective view of a first mode of realization lization of a module of the device of [Fig.l];
[0065] [Fig.3] - [Fig.3] is an exploded perspective view of another module of the device of [Fig.l];
[0066] [Fig.4] - [Fig.4] is a perspective bottom view of the device of [Fig.l] provided with a patch;
[0067] [Fig.5] - [Fig.5] is a perspective bottom view of the device of [Fig.4] after removing a protective layer from the patch;
[0068] [Fig.6] - [Fig.6] is a top sectional view of the module of [Fig.2] in a initial configuration of the device of [Fig.l];
[0069] [Fig.7] - [Fig.7] is a perspective sectional view of the device of [Fig.l] before being applied to the patient's skin;
[0070] [Fig.8] - [Fig.8] is a perspective sectional view of the device of [Fig.l] just after being applied to the patient's skin;
[0071] [Fig.9] - [Fig.9] represents an enlargement of a detail of the module of [Fig.6] in an operating configuration of the device subsequent to that of [Fig.6]
[0072] [Fig. 10] - [Fig. 10] is a sectional side view of a portion of the module of [Fig.6] in an initial configuration of the device of [Fig.l];
[0073] [Fig. 11] - [Fig. 11] is a sectional side view of the part of [Fig. 10] in an operating configuration of the device subsequent to that of [Fig. 10] and corresponding to that of [Fig.9];
[0074] [Fig. 12] - [Fig. 12] is a sectional side view of another detail of the module of [Fig.6] in an initial configuration of the device of [Fig.l];
[0075] [Fig. 13] - [Fig. 13] is a sectional side view of the detail of [Fig. 12] in an operating configuration of the device subsequent to that of [Fig. 12] and corresponding to that of figures 9 and 11;
[0076] [Fig. 14] - [Fig. 14] is a perspective sectional view of certain components of the module of [Fig.6] in an operating configuration of the device subsequent to that of [Fig.6] and corresponding to that of figures 9, 11 and 13;
[0077] [Fig. 15] and [Fig. 16] - Figures 15 and 16 are perspective views of certain components of a second embodiment of the device of the present invention in two subsequent operating configurations thereof;
[0078] [Fig. 17] - [Fig. 17] is a perspective sectional view of some of the components of Figures 15 and 16 in an operating configuration of the device subsequent to that of [Fig. 16];
[0079] [Fig. 18], [Fig. 19] and [Fig.20] - Figures 18 to 21 show an enlargement of another part of the module of [Fig.6] in four subsequent operating configurations of the device of [Fig.l];
[0080] [Fig.22] - [Fig.22] is a sectional side view of part of the device of the [Fig.l] in an operating configuration of the device subsequent to that of [Fig.8];
[0081] [Fig.23] - [Fig.23] is a sectional side view of the device of [Fig.l] in a possible operating configuration thereof in which said device is not applied to the patient's skin;
[0082] [Fig.24] - [Fig.24] is a perspective view of a component of the device of the [Fig.l];
[0083] [Fig.25] - [Fig.25] is a perspective view of part of a third mode of realization of the module of [Fig.2] when the device is not applied to the patient's skin;
[0084] [Fig.26] - [Fig.26] is a perspective view of the part of [Fig.25] just after having applied the device to the patient's skin;
[0085] [Fig.27] - [Fig.27] is a top view of the part of [Fig.25] in the confi operating figure of [Fig.26];
[0086] [Fig.28] - [Fig.28] is a perspective view of the part of [Fig.25] in a operating configuration of the device subsequent to that of figures 26 and 27;
[0087] [Fig.29] - [Fig.29] is a top view of the part of [Fig.25] in the confi operating figure of [Fig.28];
[0088] [Fig.30], [Fig.31] and [Fig.32] - Figures 30 to 32 are perspective views of the part of [Fig.25] in three operating configurations of the device subsequent to that of [Fig.28];
[0089] [Fig.33] - [Fig.33] is a sectional side view of the part of [Fig.25] in the operating configuration of [Fig.26];
[0090] [Fig.34] - [Fig.34] is a sectional side view of the part of [Fig.25] in the operating configuration of [Fig.32];
[0091] [Fig.35] - [Fig.35] is a time diagram relating to different stages of func operation implemented by the device of the present invention during its use. Detailed description of the invention
[0092] In [Fig.l], a device of the type capable of being worn on oneself for the subcutaneous administration of a medicament according to the present invention is indicated by the reference numeral 1.
[0093] The device 1 comprises an administration module 2, shown in [Fig.2], and a control module 3, shown in [Fig.3].
[0094] The device 1 is obtained by mutually coupling the administration module 2 and the control module 3. This coupling is reversible, that is to say that the two modules 2 and 3 can be decoupled after having been coupled.
[0095] One or more seals (not shown) are interposed between the administration module 2 and the control module 3 in order to ensure the sealing of the mutual coupling.
[0096] The administration module 2 is preferably disposable, while the control module 3 is preferably reusable. In other words, the module administration module 2 is configured to be applied to the patient's body only once and for a certain period of time to administer the drug, completely or in part, in one or more successive injections, even if spaced apart in time from each other. Conversely, the control module 3 can be used several times, by coupling it from time to time to a new administration module 2.
[0097] As shown in [Fig. 3], the control module 3 comprises a lower body 4 and an upper cover 5 associated with the lower body 4, preferably by ultrasonic welding. In this case, ultrasonic welding is preferable to laser welding because the latter requires the use of transparent materials which are not considered practical to use for the control module 3, since it can be customized with different colors and / or finishes.
[0098] A housing compartment 6 is defined between the lower body 4 and the upper cover 5. The housing compartment 6 contains a control unit 7, generally consisting of a printed circuit and configured to control the delivery of the drug from the delivery module 2, a power supply battery 8 configured to supply power to the control unit 7 and a motor 9 which rotates a magnetic drive rotor 9a.
[0099] A plurality of electronic components and a hardware unit that supplies power to said electronic components are provided in the control module 3.
[0100] The control module 3 further comprises a switch (not shown) configured to supply power to the control unit 7 and an activation button 3a. The patient activates the device 1 by pressing the activation button 3a.
[0101] As shown in [Fig.2], the administration module 2 comprises a main body 11 and an intermediate cover 15 associated with the main body 11 and interposed between the main body 11 and the lower body 4 of the control module 3. Preferably, the intermediate cover 15 is welded to the main body 11 by laser welding. In this case, the latter is preferable to ultrasonic welding, since the assembly of the administration module 2 takes place with all the members described below already mounted on the main body 11 and the use of ultrasonic welding would risk activating these members.
[0102] A housing compartment 10 is defined between the main body 11 and the intermediate cover 15.
[0103] As shown in [Fig. 10], the main body 11 includes an application surface 12 configured to come into contact with the patient's body.
[0104] The application surface 12 is substantially flat and defines a plane P for resting on the patient's skin.
[0105] The application surface 12 comprises a through opening 12a ([Fig.2]).
[0106] Referring again to [Fig.2], the housing compartment 10 is configured to house a plurality of components, including a cartridge 20 and a fluid path 30.
[0107] The administration module 2 further comprises an ignition magnet 2a and an NFC tag 2b on which a plurality of information is stored.
[0108] The cartridge 20 is arranged on the main body 11 and comprises a substantially cylindrical container 22, made of a plastic or glass material and containing the medicament to be administered to a patient. A pierceable septum 24 which closes the container 22 and guarantees its sterility until the use of the device 1 is arranged at one end 23 of the container 22. A piston 26 (shown in [Fig. 6]) can slide in the container 22 to administer the medicament.
[0109] As shown in [Fig.6], the fluid path 30 is also arranged on the main body 11 and is configured to be traversed by the medicament during subcutaneous administration of the medicament, allowing the transfer of the medicament from the cartridge 20 to the patient's body.
[0110] The fluid path 30 includes a piercing needle 32 configured to pierce the pierceable septum 24 (as illustrated for example in [Fig. 13]), an injection needle 34 configured to be inserted into the patient's body (as illustrated for example in [Fig. 22]), and a flexible tube 36 (illustrated for example in Figures 2 and 6) that places the aforementioned needles 32 and 34 in fluid communication.
[0111] In particular, as shown in Figures 2 and 6, the flexible tube 36 has an end portion 36a connected to a support member 42 which supports the piercing needle 32 and an opposite end portion 36b connected to a support member 62 which supports the injection needle 34.
[0112] With reference to [Fig. 6], the administration module 2 further comprises a fluid path opening system 40 configured to control the piercing of the pierceable septum 24 by the piercing needle 32 and thereby place the container 22 in fluid communication with the injection needle 34 through the piercing needle 32 and the flexible tube 36.
[0113] The support member 42 is slidably mounted on a sliding guide 44 mounted on the main body 11 (Figures 9, 12 and 13). The support member 42 is movable between a first operating position in which the piercing needle 32 is spaced from the pierceable septum 24 (as illustrated for example in Figures 10 and 12) and the fluid path 30 is closed, and a second operating position in which the piercing needle 32 has pierced the pierceable septum 24 (as illustrated for example in Figures 11 and 13), thereby opening the fluid path 30.
[0114] With reference to Figures 10 and 11, the movement of the support member 42 is achieved by providing a movement transmission member 50 comprising a worm screw 54 engaged with a rack 51 at a coupling portion 53 of the rack 51. The latter is in turn coupled to a drive member 48 which can rotate about an axis of rotation X and which can be coupled to the support member 42.
[0115] In particular, the drive member 48 comprises a substantially circular base body 48a, a coupling portion 48b configured to couple to the support member 42 and a coupling portion 48c at which a coupling portion 52 of the rack 51 is engaged. The coupling portion 52 is arranged downstream of the coupling portion 53 along the direction A.
[0116] The coupling parts 48b and 48c extend from the base body 48a on axially opposite sides relative to the axis of rotation X.
[0117] The coupling part 48b is defined by a peripheral wall 48d. The latter is provided with a through opening 48e and delimits in the coupling part 48b a substantially cylindrical zone 48g (figures 11 and 14).
[0118] The coupling portion 48c comprises a toothing 48f engaged with the coupling portion 52 of the rack 51 and extending circumferentially over a predetermined angle less than 360°, more preferably less than 180°, for example equal to approximately 90°.
[0119] As shown in [Fig. 10], the rack 51 is driven to move, towards the support member 42 along a direction A orthogonal to the axis of rotation X and substantially parallel to the plane P, by the rotation of the worm 54 which in turn is rotated by a magnetic rotor 56 (shown entirely in [Fig. 2]) mounted on the main body 11 and driven by the magnetic drive rotor 9a provided in the control module 3. Due to the coupling between the rack 51 and the toothing 48f, the movement of the rack 51 causes the rotation of the drive member 48 about the axis of rotation X.
[0120] As shown in [Fig.9], the support member 42 is subjected to a pushing action along a direction B opposite to the direction A by an elastic element 46, in particular a torsion spring. This spring comprises a plurality of turns arranged around an axis orthogonal to the axis of rotation X and tends to push the support member 42 from the first operating position to the second operating position.
[0121] As shown in Figures 10, 11 and 14, the support member 42 comprises a body 42a and a stop member 43 projecting from the body 42a and dimensioned to be able to pass through the through opening 48e. In particular, the stop member 43 is defined by a cylindrical pin 43a which extends cantilevered from the outer side surface of the body 42a.
[0122] Until the drive member 48 rotates around the axis of rotation X by a angle less than a predetermined value, the support member 42 remains in the first operating position due to the mutual abutment between the abutment element 43 and the outer surface of the peripheral wall 48d. This mutual abutment counteracts the thrust action exerted by the elastic element 46 on the support member 42 ([Fig. 10]).
[0123] As soon as the rotation angle of the drive member 48 reaches the predetermined value mentioned above, the support member 42 is free to move from the first operating position to the second operating position along the direction B due to the fact that the stop element 43 is located at the through opening 48e ([Fig. 11]) and can pass through it due to the pushing action exerted by the elastic element 46, so as to arrange itself in the area 48g of the coupling part 48b ([Fig. 14]).
[0124] Figures 15 to 17 show a second embodiment of the fluid path opening system 40, which can also be used in the device 1 of the present invention as an alternative to that described above. Elements of this second embodiment that are identical or equivalent to those described above are designated by the same reference numeral.
[0125] In this second embodiment, the turns of the torsion spring which defines the elastic element 46 are arranged around an axis orthogonal to the axis of rotation X and positioned closer to the rack 51 relative to the axis of the torsion spring of the embodiment described above.
[0126] Furthermore, in the embodiment of Figures 15 to 17, the stop element 43 is defined by a rectilinear rib 43b arranged on the outer lateral surface of the body 42a.
[0127] In [Fig. 15], the drive member 48 is shown in a first angular position, while in [Fig. 16], the drive member 48 is shown in a second angular position. These angular positions are functionally similar to those of Figures 10 and 11 of the first embodiment described above.
[0128] In [Fig. 17], the drive member 48 is shown in another angular position subsequent to that of [Fig. 16]. When the drive member reaches the angular position of [Fig. 17], the rib 43b, which has previously entered the area 48g of the coupling portion 48b ([Fig. 16]), is located at an inner surface of the peripheral wall 48d and cannot exit the area 48g. In this way, the drive member 48 hinders a possible tendency of the support member 42 to move from the second operating position to the first operating position.
[0129] As shown in [Fig.6] and Figures 18 to 23, the administration module 2 also includes an injection needle moving mechanism 60, configured to move the injection needle 34, at the start of the administration of the therapy from a rest position, in which the injection needle 34 is entirely arranged inside the device 1 and does not protrude from the plane P of the device 1 (Figures 18 and 19), to an injection position in which the injection needle 34 protrudes at least partially from the plane P of the device 1 (Figures 20 and 22) through the through opening 12a, and at the end of the administration of the therapy from the injection position to the rest position ([Fig.21]).
[0130] The support member 62 which supports the injection needle 34 is movable orthogonally to the plane P between a first operating position in which the injection needle 34 is in the rest position and a second operating position in which the injection needle 34 is in the injection position.
[0131] The support member 62 has a substantially cylindrical shape and has an outer lateral surface 62a to which the end portion 36b of the flexible tube 36 is connected.
[0132] As shown in [Fig. 23], the support member 62 is subjected to a pushing action exerted by a compression spring 64. This pushing action tends to push the support member 62 towards its first operating position, so as to maintain the injection needle 34 in the rest position before use of the device 1 ([Fig. 18]) and to return the injection needle 34 to the rest position after administration of the therapy ([Fig. 21]).
[0133] In particular, the compression spring 64 is arranged between the main body 11 and an inner surface 62b of the support member 62 facing the plane P.
[0134] The compression spring 64 extends along an axis C orthogonal to the plane P, while the injection needle 34 extends along an axis N distinct and parallel to the axis C. The axis N is arranged close to the outer lateral surface 62a of the support member 62.
[0135] With reference to Figures 18 to 23, the injection needle moving mechanism 60 comprises a pushing member 63 configured to move the support member 62 and, thus, the injection needle 34. The pushing member 63 can move from a first service position (Figures 18 and 19) in which the support member 62 is in the first operating position and the injection needle 34 is in the rest position to a second service position (Figures 20, 22 and 23) in which the support member 62 is in the second operating position and the injection needle 34 is in the injection position.
[0136] The thrust member 63 is subjected to a thrust action exerted by a compression spring 65 (Figures 22 and 23). This thrust action tends to push the thrust member 63 towards the second service position.
[0137] The compression spring 65 is arranged between the intermediate cover 15 and an inner surface 63a of the thrust member 63 facing away from the plane P.
[0138] The compression spring 65 extends along an axis D orthogonal to the plane P. The axis D is distinct from the axis C and the axis N, and parallel to them.
[0139] The compression spring 65 has a higher elastic constant than that of the compression spring 64.
[0140] The injection needle moving mechanism 60 has two main operating configurations.
[0141] In a first operating configuration, illustrated in [Fig. 20], the pushing member 63 is coupled to the support member 62 and the force exerted by the compression spring 65 on the pushing member 63 moves it from the first operating position to the second operating position, moving the support member 62 from the first operating position to the second operating position. During the movement of the support member 62, the compression spring 64 is loaded.
[0142] In a second operating configuration, shown in [Fig. 21], the pushing member 63 is decoupled from the support member 62 and the force exerted by the compression spring 64 on the support member 62 moves it from the second operating position to the first operating position. When the injection needle moving mechanism 60 is in the second operating configuration, the pushing member 63, which is decoupled from the support member 62, remains in the second operating position due to the pushing action exerted by the compression spring 65.
[0143] The thrust member 63 has a substantially cylindrical shape and is rotatable about the axis D from a first angular position ([Fig.20]) in which the injection needle movement mechanism 60 is in the first operating configuration to a second angular position ([Fig.21]) in which the injection needle movement mechanism 60 is in the second operating configuration.
[0144] A stop element 62c (visible in [Fig.21]) extends from the outer lateral surface 62a of the support member 62 towards the thrust member 63 and a thrust element 63c extends from an outer lateral surface 63b of the thrust member 63 towards the support member 62.
[0145] When the injection needle moving mechanism 60 is in the first operating configuration, the pushing element 63c is coupled to the stop element 62c and exerts a pushing action against the latter ([Fig. 20]), whereas, when the injection needle moving mechanism 60 is in the second operating configuration, the pushing element 63c is decoupled from the stop element 62c ([Fig. 21]).
[0146] The rotation of the thrust member 63 from the first angular position to the second angular position, and consequently the transition of the injection needle moving mechanism 60 from the first operating configuration to the second operating configuration, is driven by an instruction member 61 arranged concentrically to the pushing member 63 and outside the latter.
[0147] The instruction member 61 has a substantially cylindrical shape and is driven to rotate about the axis D initially from an angular stop position ([Fig.18]) in which the thrust member 63 is in the first angular position and the instruction member 61 is coupled to the thrust member 63 and maintains the latter in the first service position, towards a first angular release position ([Fig.20]) in which the thrust member 63 is still in the first angular position and the instruction member 61 is decoupled from the thrust member 63 allowing the thrust member 63 to reach the second service position.
[0148] A protruding member 63d extends from the outer side surface 63b of the thrust member 63 on the opposite side relative to the thrust member 63c.
[0149] The instruction member 61 comprises a stop surface 61e which, when the instruction member 61 is in the angular stop position, abuts against the projecting element 63d (Figures 18 and 19).
[0150] The instruction member 61 further comprises a seat 61a which, when the instruction member 61 is in the first angular release position, houses the projecting element 63d ([Fig.20]), and a through opening 61b ([Fig.18]) through which the pushing element 63c passes to allow the pushing member 63 to couple to the support member 62.
[0151] When, following the rotation of the instruction member 61, the seat 61a is below the projecting element 63d, the pushing member 63 is free to move from the first operating position to the second operating position due to the pushing action exerted by the compression spring 65. Consequently, the support member 62 is moved from the first operating position to the second operating position due to the movement of the pushing member 63 from the first operating position to the second operating position and, consequently, the thrust exerted by the pushing element 63c on the stop element 62c, this thrust no longer being hindered by the stop surface 61e of the instruction member 61. The injection needle 34 is thus extracted from the device 1.
[0152] The pushing element 63c passes through the through opening 61b of the instruction member 61 both when the pushing member 63 is in the first service position and when the pushing member 63 is in the second service position.
[0153] Then, the instruction member 61 is rotated about the axis D from the first angular release position ([Fig.20]) to a second angular release position ([Fig.21]) in which the thrust member 63 is in the second angular position. This rotation causes a similar rotation of the thrust member 63 because the projecting element 63d is housed in the seat 61a.
[0154] The housing of the projecting element 63d in the seat 61a therefore allows both the transition of the pushing member 63 from the first service position to the second service position due to the thrust exerted on the pushing member 63 by the compression spring 65, with the consequent extraction of the injection needle 34 from the device 1 ([Fig. 20]), and the transfer of the rotary movement of the instruction member 61 to the pushing member 63 when it is in the second service position ([Fig. 21]), with the consequent release of the support member 62 by the pushing member 63 and the consequent retraction of the injection needle 34 inside the device 1 due to the thrust exerted on the support member 62 by the compression spring 64.
[0155] The instruction member 61 comprises a coupling portion 61c engaged with the worm screw 54. The coupling portion 61c is a toothing extended circumferentially over a predetermined angle, preferably less than 180°.
[0156] As shown in [Fig.22], a suitably shaped plate 630 is arranged above the pusher member 63 and the support member 62 to prevent rotation of the pusher member 63 about the axis D. This plate 630 also allows all components of the injection needle moving mechanism 60 to be aligned and retention of the compression springs 64 and 65 along the direction of the axis D to be ensured.
[0157] As shown in Figures 7, 8, 22 to 24, the administration module 2 also comprises a protective element 70 disposed around the injection needle 34 and configured to cover the tip of the injection needle 34 if the latter is in the injection position, or moves therein, for example due to a malfunction or failure of the injection needle moving mechanism 60, before applying the device 1 to the patient's skin, or if the injection needle 34 accidentally remains in the injection position during removal of the device 1 from the patient's skin, for example due to accidental or intentional removal by the patient before the end of the administration of the therapy ([Fig.23]).
[0158] The protective element 70 is movable between a first operating position (Figures 7 and 23) in which it projects from the device 1 and covers the tip of the injection needle 34 if the injection needle 34 is in the injection position ([Fig.23]), and a second operating position (Figures 8 and 22) in which it does not project from the device 1.
[0159] The protective element 70 is shown in detail in [Fig.24].
[0160] The protective element 70 is subjected to a pushing action exerted by a elastic element 72, in particular by a compression spring. This pushing action tends to maintain the protective element 72 in the first operating position both before applying the device 1 to the patient's skin and when the device 1 is removed from the patient's skin ([Fig. 7]) and to allow the protective element 70 to reach the second operating position when the device 1 is applied to the patient's skin (Figures 8 and 22).
[0161] In particular, the elastic element 72 is arranged between the intermediate cover 15 and an inner surface 70e which is inside the protective element 70 and which faces towards the intermediate cover 15 (figures 22 and 23).
[0162] The elastic element 72 extends along an axis E orthogonal to the plane P. The axis E is distinct from the axes C, D and N, and parallel to them.
[0163] With reference to [Fig.6], the administration module 2 comprises a stop mechanism 170 configured to stop the movement of the protection element 70.
[0164] In particular, the protective element 70 comprises a locking element 70b configured to lock the protective element 70 in the first operating position when the device 1 is removed from the patient's skin. The locking of the protective element 70 occurs when the locking element 70b interferes with a stop element 74 associated with the rack 51 at a coupling portion 55 of the rack 51 which is arranged upstream of the coupling portion 52 and downstream of the coupling portion 53 along the direction A, i.e. interposed between the coupling portion 53 and the coupling portion 52 (Figures 20 and 21).
[0165] The device 1 has a reversible initial configuration in which the protective element 70 is free to move between the first operating position and the second operating position and vice versa before the device 1 is applied to the patient's skin. In this configuration, the locking element 70b, integral with the protective element 70, is in a distal position relative to the stop element 74.
[0166] The device 1 has an irreversible final configuration in which the protection element 70 is locked in the first operating position. In this configuration, the locking element 70b is in contact with the stopping element 74.
[0167] Due to the movement of the rack 51 along the direction A, the stop element 74 moves along this direction A from an initial position to a final position.
[0168] In the initial position, the stop element 74 and the locking element 70b are not superimposed on each other and the device 1 is in the initial reversible configuration (Figures 18 and 19), while in the final position, the stop element 74 and the locking element 70b are superimposed on each other and the device 1 is in the final irreversible configuration (figures 20 and 21).
[0169] Preferably, the locking element 70b is made of a rigid material and the stopping element 74 is made of a deformable material.
[0170] The changeover from the reversible configuration to the irreversible configuration occurs when the stop element 74 is in the final position and the locking element 70b moves along a direction F ([Fig.23]) orthogonal to the direction A, passing beyond the stop element 74. This movement occurs when the device 1 is removed from the patient's skin due to the movement of the protective element 70 from the second operating position to the first operating position due to the pushing action exerted by the elastic element 72.
[0171] The movement of the locking element 70b along the direction F first causes the interference between the locking element 70b and the stop element 74, and then the transition of the locking element 70b to the opposite side of the stop element 74 due to the deformation of the latter.
[0172] In particular, the stop element 74 comprises a first surface facing away from the plane P and a second surface facing towards the plane P.
[0173] The first surface allows deformation of the stop member 74 as a result of interference with the locking member 70b and movement of the locking member 70b along the direction F from the second operating position to the first operating position.
[0174] The first surface is preferably inclined relative to a plane orthogonal to the direction F, thus facilitating the transition of the locking element 70b from one side to the other side of the stop element 74 as a result of the deformation of the latter.
[0175] The second surface instead defines a notch which, when the device 1 is in the final irreversible configuration, prevents the locking element 70b from moving from the first operating position. The second surface is preferably orthogonal to the direction F.
[0176] As shown in [Fig.24], the protective element 70 has a base 70a provided with a through hole 71 to allow the transition of the injection needle 34 during movement of the injection needle 34 between the rest position and the injection position when the protective element 70 is in the second operating position.
[0177] The base 70a comprises a raised edge 70b defining in the base 70a a recess 70c which houses the tip of the injection needle 34 both when the protection element 70 is in its second operating position and the injection needle 34 is in the rest position ([Fig.8]) and when the protection element 70 is in its first operating position and the injection needle 34 is in the injection position ([Fig.23]).
[0178] As shown in Figures 33 and 34, the through hole 71 may be closed by a pierceable septum 271.
[0179] The device 1 comprises a position sensor 76 (figures 7 and 8) adapted to detect contact of the device 1 with the patient's skin.
[0180] The position sensor 76 comprises a magnet 77 associated in one piece with the protection element 70 and a Hall effect sensor 78 arranged in the control module 3 near the magnet 77.
[0181] The magnet 77 is entirely housed in a seat 75 formed in the protective element 70 ([Fig.24]).
[0182] The locking element 70b is associated with the seat 75 near the magnet 77.
[0183] As shown in Figures 2 and 5, the device 1 further comprises a flexible sleeve 80 associated in a watertight manner with the application surface 12 of the administration module 2 around the through opening 12a.
[0184] The flexible sleeve 80 is made of a medical grade silicone material.
[0185] The flexible sleeve 80 surrounds the protective element 70 and comprises a surface base 80a having an inner surface integrally associated with the outer surface of the base 70a of the protective element 70.
[0186] In the embodiment illustrated here, the flexible sleeve 80 is defined by a bellows-type membrane having a frustoconical shape.
[0187] The flexible sleeve 80 is arranged entirely inside the administration module 2 when the protective element 70 is in its second operating position ([Fig.8]).
[0188] The base surface 80a of the flexible sleeve 80 covers the through hole 71 of the protective member 70 and can be pierced by the injection needle 34 when the injection needle 34 moves from the rest position to the injection position.
[0189] The flexible sleeve 80 comprises an annular end portion 83 fixed to the application surface 12 of the administration module 2 by means of a compression ring 83a (Figures 23, 33 and 34). The latter is welded to the application surface 12 by ultrasonic welding.
[0190] The annular end portion 83 is thus interposed between the application surface 12 and the compression ring 83a and prevents water and powders from accessing the interior of the device 1 via the through opening 12a of the application surface 12.
[0191] As shown in Figures 4 and 5, a patch 90 is applied to the application surface 12 of the main body 11 of the administration module 2.
[0192] The patch 90 comprises an adhesive layer 91 integrally attached to the application surface 12 and a protective layer 92 removably attached to the adhesive layer 91. Before carrying out the administration of the therapy, the protective layer 92 is removed ([Fig.5]) and the device 1 is attached to the patient's skin through the layer adhesive 91.
[0193] The device 1 further comprises a cap 100 fixed in one piece to the protective layer 92. In particular, the cap 100 comprises a collar 101 fixed to the protective layer 92 by interposition of a double adhesive element 101a.
[0194] The cap 100 is made of a rigid material and is shaped to completely house, with clearance, the protective element 70 and the flexible sleeve 80 which surrounds the protective element 70 when the latter is in its first operating position.
[0195] In the embodiment illustrated here, the cap 100 has a frustoconical shape.
[0196] As already mentioned, the protective element 70 is initially in its extended configuration of [Fig. 5] and the hood 100 covers the protective element 70, as shown in [Fig. 4].
[0197] Before applying the device 1 to the patient's skin, the patient removes the protective layer 92 from the patch 90, simultaneously removing with it also the cap 100 and thus exposing the protective element 70 and the adhesive layer 91 of the patch 90.
[0198] The patient can then proceed to apply the device 1 to his skin by securing it through the adhesive layer 91 of the patch 90. The patient's skin counteracts the pushing action exerted by the elastic element 72 and causes the protective element 70 to retract inside the administration module 2, bringing the magnet 77 closer to the Hall effect sensor 78 and thus allowing the control unit 7 to establish that the device 1 is in contact with the patient's skin and to activate the administration of the therapy.
[0199] The administration of the therapy comprises the controlled movement of the piston 26 inside the container 22 towards the pierceable septum 24. For this purpose, the administration module 2 comprises a drug delivery mechanism 110 ( [Fig. 6]) which is activated, driven by the control unit 7, by the same magnetic rotor 56 which drives the motion transmission member 50 and, consequently, the rotation of the worm screw 54. As already mentioned, the latter causes both the activation of the injection needle movement mechanism 60 and the movement of the rack 51 along the direction A, which in turn causes both the opening of the fluid path 30 and the locking of the protective element 70 in the first operating position after the removal of the device 1 from the patient's skin.
[0200] In particular, the control unit 7 drives the magnetic rotor 56 alternately in a first rotational direction to activate the motion transmission member 50 and in a second rotational direction opposite to the first rotational direction to cause the delivery of the medicament from the container 22 upon activation of another motion transmission member 111 ([Fig.6]) arranged in the main body 11 on the side opposite to the transmission member of movement 50 relative to the magnetic rotor 56 and the worm screw 54.
[0201] Figures 25 to 34 show another embodiment of a device which differs from the device 1 described above with respect to certain details relating to the injection needle displacement mechanism 60, the protective element 70 and the flexible sleeve 80. The elements and / or members of this embodiment which are identical or equivalent to those described above are indicated by the same reference numeral.
[0202] In this case, the flexible sleeve 80 does not have the base surface 80a and the protective element 70 has a base 70a having a diameter greater than that of the adjacent end portion of the flexible sleeve 80.
[0203] Also in this case, a support member 62 which supports the injection needle, a pushing member 63 and an instruction member 61 equivalent to those described above are provided.
[0204] [Fig.25] shows the operating configuration in which the injection needle 34 is in the rest position and the protective element 70 and the flexible sleeve 80 protrude from the device.
[0205] Figures 26 and 33 show the operating configuration in which the device is applied to the patient's skin. The injection needle 34 is still in the rest position and the protective element 70 and the flexible sleeve 80 are pushed inside the device. Only the base 70a of the protective element 70 remains protruding from the device.
[0206] [Fig.28] shows the operating configuration in which the device is applied to the patient's skin and the injection needle 34 is in the injection position to administer the therapy. The protective element 70 and the flexible sleeve 80 are still inside the device.
[0207] [Fig.30] shows the operating configuration in which the device is still applied to the patient's skin, but the injection needle 34 has been returned to the rest position.
[0208] [Fig.31] shows the operating configuration in which the device is removed from the patient's skin at the end of therapy delivery. The protective element 70 and the flexible sleeve 80 protrude from the device.
[0209] Figures 32 and 34 show the operating configuration in which the device is removed from the patient's skin before the end of therapy delivery and the injection needle 34 is still in the injection position. The shield member 70 and the flexible sleeve 80 protrude from the device and the shield member 70 is locked in position outside the device.
[0210] In this embodiment, the instruction member 61 comprises two articulated arms 631 arranged on opposite sides with respect to the pushing element 63c ([Fig.27]). As illustrated in [Fig.29], each articulated arm 631 comprises a first lever 631a hinged to the outer lateral surface 61g of the instruction member 61 and a second lever 631b hinged to the first lever 631a. Each second lever 631b is slidably coupled to a respective guide 633 and includes a respective stop member 174 whose shape and material are similar to those of the stop member 74 described previously.
[0211] The protective element 70 comprises two locking elements 171 arranged on diametrically opposite sides with respect to the stop element 62c and configured to cooperate with the stop elements 174 ([Fig.27]).
[0212] During rotation of the instruction member 61, the stop elements 174 move closer to the respective locking elements 171 until each of them is at the level of the respective locking element 171.
[0213] In the operating configuration of Figures 25 to 30, the two locking elements 171 are arranged on one side relative to the stopping elements 174, in particular close to the shaped plate 630. This is due to the fact that the protective element 70 does not protrude from the device.
[0214] When the protective element 70 exits the device following removal of the device from the patient's skin, the locking elements 171 pass beyond the stopping elements 174 locking the protective element 70 in the position shown in [Fig. 31]. In this operating configuration, the injection needle 34 has previously been returned inside the device.
[0215] If, after removal of the device from the patient's skin, the injection needle 34 remains outside the device, as in the operating configuration of [Fig. 32], the protective element 70 and the flexible sleeve 80 protect the patient from any contact with the injection needle 34.
[0216] Also with reference to [Fig.35], the sequence of operating steps implemented by the device 1 during its use is described in detail below.
[0217] During a first time interval preceding the instant t0 when the patient activates the device 1 by acting on the activation button 3a, the patient receives separately the administration module 2 and the control module 3 and couples them. In this time interval, the device 1 is in standby mode, that is to say the energy supply battery 8 only powers some of the electronic components present in the control module 3 thanks to the provision of a hardware unit which cuts off the energy supply to all the electronic components except those associated with: the ignition magnet 2a, the switch which supplies energy to the control unit 7, the activation button 3a for activating the device 1 and the NFC tag 2b. The motor 9 is not supplied with energy.
[0218] After mutual coupling, the administration module 2 and the control module 3 are temporarily coupled not only mechanically but also via a magnetic coupling established by the proximity between the magnetic drive rotor 9a provided in the control module 3 and the magnetic rotor 56 provided in the administration module 2. The control unit 7 is energized by a change in the magnetic field generated by the mutual approach between the ignition magnet 2a and the switch that supplies power to the control unit 7 which are closer. This mutual approach triggers the above-mentioned switch, which energizes the control unit 7.
[0219] Once powered up, the control unit 7 performs a self-diagnosis.
[0220] In addition, after power-up, the control unit 7 interrogates the NFC tag 2b by reading the information stored therein. In particular, the control unit 7 performs any or all of the following actions: checking whether the administration module 2 has already been used, checking whether the administration module 2 is configured to administer a correct dosage of the drug, establishing the method of administering the drug, establishing the speed of administering the drug.
[0221] After power-up, the control unit 7 also reads the signal from the position sensor 76 to establish whether the device 1 is in contact with the patient's skin.
[0222] In particular, the patient removes the protective layer 92 from the patch 90, simultaneously removing the cap 100, and applies the device 1 to his skin.
[0223] In the time interval mentioned above preceding the instant t0 and before the application of the device 1 to the patient's skin: - the fluid path 30 is closed, that is to say that the piercing needle 32 is in a distal position relative to the pierceable septum 24 and the elastic element 46 is compressed; - the protective element 70 is in its first operating position, that is to say it protrudes from the device 1 and the elastic element 72 is extended; - due to the distance between the magnet 77 and the Hall effect sensor 78, the position sensor 76 signals to the control unit 7 that the device 1 has not yet been applied to the patient's body; - the injection needle movement mechanism 60 is deactivated, that is to say the injection needle 34 is in the rest position, inside the device 1; - the flexible sleeve 80 is extended.
[0224] In the time interval mentioned above preceding the instant t0, after application of the device 1 to the patient's skin: - the fluid path 30 remains closed; - the protective element 70 is in its second operating position, that is to say it is arranged inside the device 1 and the elastic element 72 is compressed; - due to the mutual approach between the magnet 77 and the Hall effect sensor 78, the position sensor 76 signals to the control unit 7 that the device has been applied to the patient's body and that the control unit 7 can be activated for therapy administration; - the injection needle movement mechanism 60 remains deactivated; - the flexible sleeve 80 is folded inside the device 1.
[0225] If the control unit 7 does not detect the signal from the position sensor 76 within a predetermined time, the control unit 7 turns off and the device 1 returns to standby mode.
[0226] At this stage (i.e. at time t0), the device 1 is put into operation by the patient by pressing the activation button 3a. The motor 9 is activated and the control unit 7 orders a series of operations which do not require any action on the part of the patient.
[0227] In a time interval tl following the time t0 and which lasts for example 10 to 15 seconds, the magnetic rotor 56 is rotated in the first direction of rotation by the motor 9 and activates the movement transmission member 50, which in turn simultaneously activates the fluid path opening system 40 (the piercing needle 32 pierces the pierceable septum 24 and the elastic element 46 extends) and the injection needle displacement mechanism 60 without however moving the injection needle 24, which remains in the rest position.
[0228] In particular, the rotation of the worm screw 54 causes the rack 51 to move along the direction A and the consequent rotation of the drive member 48 and the opening of the fluid path 30. This rotation also causes the instruction member 61 to rotate, which moves from the angular stop position of [Fig. 18] to another angular stop position, shown in [Fig. 19]. This rotation does not cause any rotation of the thrust member 63, which remains in the first operating position because the projecting element 63d remains in abutment against the abutment surface 61e.
[0229] In a time interval t2 following the time interval t1 and lasting for example 8 to 12 seconds, the magnetic rotor 56 is rotated in the second direction of rotation by the motor 9 and activates the motion transmission member 111, causing the piston 26 to move inside the container 22. Such a movement causes the medication to exit through the piercing needle 32, but not the administration of the medication through the injection needle 34. The thrust exerted by the piston 26 on the medication causes the air contained in the path to exit fluidics 30 (priming phase).
[0230] In a time interval t3 following the time interval t2 and which lasts for example 8 to 12 seconds, the magnetic rotor 56 is rotated again in the first direction of rotation by the motor 9 and activates the movement transmission member 50 again, causing the reactivation of the injection needle movement mechanism 60.
[0231] In particular, the rotation of the worm screw 54 causes a further rotation of the instruction member 61 which moves from the angular stop position of [Fig. 19] to the first angular release position of [Fig. 20]. This rotation causes the displacement of the pushing member 63 from the first operating position to the second operating position and, consequently, the displacement of the support member 62 (and therefore of the injection needle 34) from the first operating position (injection needle 34 in the rest position) to the second operating position (injection needle 34 in the injection position). The injection needle 34 thus penetrates the patient's skin.
[0232] In a time interval t4 following the time interval t3 and lasting for example 2 to 5 seconds, the magnetic rotor 56 is rotated again in the second direction of rotation by the motor 9 and activates the motion transmission member 111 again, causing the piston 26 to move inside the container 22 which this time causes the administration of the medication into the patient's body through the injection needle 34. In this phase, it may still happen that a very limited quantity of air, remaining inside the fluid path 30 after the priming phase, is expelled from the fluid path.
[0233] Following the time interval t4, the motor 9 again drives the magnetic rotor 56 in the first direction of rotation by reactivating the motion transmission member 50 and causing the reactivation of the injection needle movement mechanism 60.
[0234] In particular, the rotation of the worm screw 54 causes a further rotation of the instruction member 61 which moves from the first angular release position of [Fig. 20] to the second angular release position of [Fig. 21]. This rotation causes a similar rotation of the thrust member 63 due to the fact that the projecting element 63d is housed in the seat 61a and, consequently, the decoupling between the thrust member 63c and the stop member 62c. At this stage, the force exerted by the compression spring 64 on the support member 62 moves it from the second operating position to the first operating position, leaving the thrust member 63 in the second service position. The injection needle 34 thus returns to the rest position, i.e. inside the device 1.
[0235] The control unit 7 emits an end of therapy signal n seconds after having caused the instruction member 61 to move from the first angular release position of [Fig.20] to the second angular release position of [Fig.21], in order to be sure that the patient can remove the device from his skin when the injection needle 34 has returned to the rest position, i.e. it is inside the device 1.
[0236] The emission of the end of therapy signal by the control unit is communicated to the patient by visual and / or acoustic signals.
[0237] The patient can then remove the device 1 from his skin.
[0238] Removing the device 1 from the patient's body causes the protective element 70 (and consequently the flexible sleeve 80) to move from the second operating position (protective element 70 inside the device 1 and the flexible sleeve 80 folded inside the device 1) to the first operating position (protective element 70 outside the device 1 and the flexible sleeve 80 extended outside the device 1) due to the thrust exerted on the protective element 70 by the elastic element 72 and, consequently, the locking of the protective element 70 in the first operating position due to the movement of the locking element(s) 70b, 171 from one side to the other side of the stop element(s) 74, 174 and the stop between the locking element(s) 70b, 171 and the second surface of the stop element 74, 174 facing plane P.
Claims
Claims
1. Device (1) for subcutaneous administration of a drug, comprising: - a cartridge (20) comprising a container (22) containing the medicament, a piston (26) slidable in said container (22) and a pierceable septum (24) coupled to one end (23) of said container (22); - a piercing needle (32) configured to pierce the pierceable septum (24); - an injection needle (34) configured to inject the medicament into a patient, said injection needle (34) defining, with said piercing needle (32), a fluid path (30) configured to be traveled by the medicament during subcutaneous administration of the medicament; - a fluid path opening system (40) configured to partially insert the piercing needle (32) into the pierceable septum (24) and thereby place the injection needle (34) in fluid communication with the container (22) through the piercing needle (32); - an injection needle moving mechanism (60) configured to move the injection needle (34) between a rest position in which the injection needle (34) is fully disposed within the device (1) and an injection position in which the injection needle (34) protrudes at least partially from the device (1) - a drug delivery mechanism configured to controllably move the plunger (26) in the container (22) toward the pierceable septum (24); - a rotor (56) configured to control the fluid path opening system (40), the injection needle moving mechanism (60) and the drug delivery mechanism (110); - a control unit (7) configured to drive the rotor (56) alternately in a first direction of rotation and in a second direction of rotation opposite to the first direction of rotation; - a first motion transmission member (50) connected to the rotor (56) and configured to drive the fluid path opening system (40) and the injection needle movement mechanism (60) by rotation of the rotor (56) in said first direction of rotation - a second motion transmission member (111) connected to the rotor (56) and configured to drive the drug delivery mechanism (110) by rotation of the rotor (56) in said second direction of rotation.
2. Device (1) according to claim 1, wherein said first motion transmission member (50) is configured to activate the fluid path opening system (40) when the rotor (56) rotates in said first rotational direction for a first time interval and the injection needle moving mechanism (60) when the rotor (56) rotates in said first rotational direction for a second time interval.
3. Device (1) according to claim 2, wherein said second time interval is later than said first time interval.
4. Device (1) according to claim 3, comprising: - a protective element (70) movable between a first operating position in which the protective element (70) protrudes from the device (1) and a second operating position in which the protective element (70) does not protrude from the device (1); - a stop mechanism (170) configured to stop the movement of the protective element (70); wherein the stop mechanism (170) comprises a stop element (74) and the protective element (70) comprises a locking element (70b) configured to cooperate with the stop element (74) and to lock the protective element (70) in the first operating position when the device (1) is removed from the patient's skin;wherein said motion transmission member (50) is configured to drive the stopping mechanism (170) when the rotor (56) rotates in said first rotational direction for a given time interval.;
5. Device (1) according to claim 4, wherein said given time interval coincides at least in part with said second time interval.
6. Device (1) according to any one of the preceding claims, wherein said first motion transmission member (50) comprises a rack (51) movable along a first direction (A) and a worm screw (54) coupled to the rack (51).
7. Device (1) according to claim 6, wherein said worm screw (54) is coupled to an instruction member (61) which controls the injection needle movement mechanism (60).
8. Device (1) according to claim 6 or 7, wherein said rack (51) comprises a first coupling portion (52) configured to drive a drive member (48) of the fluid path opening system (40) during movement of the rack (51) along said first direction (A) and a second coupling portion (53) arranged upstream of said first coupling portion (52) along said first direction (A) and coupled to said worm screw (54).
9. Device (1) according to any one of claims 6 to 8 when dependent on claim 4, wherein the stop element (74) is associated with a third coupling part (55) of the rack (51) arranged upstream of the first coupling part (52) along said first direction (A).
10. A device (1) according to claim 9 when dependent on claim 8, wherein said third coupling portion (55) is interposed between said first coupling portion (52) and said second coupling portion (53).
11. A method for performing subcutaneous administration of a medicament through a device (1) according to any one of the preceding claims, comprising, in this order: - detecting whether the device (1) is applied to the patient's skin; - activating the fluid path opening system (40) by the first motion transmission member (50) by rotating the rotor (56) in said first rotational direction for a first time interval; - driving the medicament delivery mechanism (110) by the second motion transmission member (111) by rotating the rotor (56) in said second rotational direction for a third time interval, causing the piston (26) to move into the container (22) without administering the medicament through the injection needle (34);- driving the injection needle displacement mechanism (60) by the first motion transmission member (50) by rotating the rotor (56) in said first direction of rotation for a second time interval, causing the displacement of; the injection needle (34) from the rest position to the injection position - driving the drug delivery mechanism (110) by the second motion transmission member (111) by rotating the rotor (56) in said second direction of rotation for a fourth time interval, causing the piston (26) to move into the container (22) and the drug to be delivered through the injection needle (34).
12. The method of claim 11, further comprising, after driving the drug delivery mechanism (110) by the second motion transmission member (111) by rotating the rotor (56) in said second rotational direction during said fourth time interval: - driving the injection needle moving mechanism (60) by the first motion transmission member (50) by rotating the rotor (56) in said first rotational direction during a fifth time interval, causing the injection needle (34) to move from the injection position to the rest position.
13. Method according to claim 11 or 12 and according to the device of claim 4, further comprising, after having activated the fluid path opening system (40) by the first motion transmission member (50) by rotating the rotor (56) in said first direction of rotation during said first time interval and before removing the device (1) from the patient's skin: - driving the stopping mechanism (170) of the protective element (70) by the first motion transmission member (50) by rotating the rotor (56) in said first direction of rotation during a given time interval.
14. The method of claim 13, wherein said given time interval at least partly coincides with said second time interval.
15. A method according to claim 13 or 14, wherein activating the fluid path opening system (40) and driving the stopping mechanism (170) of the protective element (70) comprises moving said rack (51) along said first direction (A).
